Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HTD4010 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 50mg in SAD | EXPERIMENTAL | single dose of 50mg HTD4010 or placebo injectable in healthy volunteers |
| 100mg in SAD | EXPERIMENTAL | single dose of 100mg HTD4010 or placebo injectable in healthy volunteers |
| 200mg in SAD | EXPERIMENTAL | single dose of 200mg HTD4010 or placebo injectable in healthy volunteers |
| 300mg in SAD | EXPERIMENTAL | single dose of 300mg HTD4010 or placebo injectable in healthy volunteers |
| Name | Type | Description |
|---|---|---|
| HTD4010 | DRUG | injectable solution |
For volunteers in SAD: Inclusion Criteria: 1. Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2 2. Non-diabetic, fasting plasma glucose \< 5.6 mmol/L 3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral ...
HTD4010 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential role in managing this metabolic condition.
HTD4010 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is advancing this small molecule through clinical development for Type 2 Diabetes Mellitus.
HTD4010 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for Type 2 Diabetes Mellitus.
HTD4010 has one completed Phase 1 clinical trial, identified as NCT02538848, titled "Study of HTD4010 in Healthy Volunteers." This randomized, double-blind, controlled study enrolled 32 participants in Australia and included healthy volunteers aged 18 years and older.
HTD4010 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Type 2 Diabetes Mellitus. The completed Phase 1 trial was conducted in healthy volunteers, and the drug has not yet progressed to later-stage trials or received regulatory approval.